Venus Remedies secures marketing authorization from UK MHRA for Cisplatin

25 Apr 2023 Evaluate

Venus Remedies has secured marketing authorization from the UK MHRA for Cisplatin, a chemotherapy drug used as a first-line treatment for advanced ovarian cancer, testicular cancer and bladder carcinoma. This marketing authorisation granted to Venus Pharma GmbH, the German subsidiary of Venus Remedies, by one of the world's most stringent healthcare regulatory agencies will enable the company to offer its affordable range of cancer drugs to the National Health Service (NHS) in the UK and neighbouring countries.

The registration for Cisplatin will also expedite the process of registering the oncology products of Venus Remedies in many other countries around the world which consider the UK as a reference country for fast-tracking registration and open opportunities for supplying unregistered products to several markets globally.

The global market size of Cisplatin was valued at $394.5 million in 2021 and is expected to grow to $661.16 million by 2027 at a CAGR of 8.99%. The UK holds at least 5% of the global market share for this drug.

Venus Remedies is one of the handful player in pharmaceutical sector to launch world global injectable manufacturers. It has world-class manufacturing facilities in Panchkula and Baddi (in India) and Werne (in Germany) and research and development center in Venus Medicine Research Centre (in India).

Venus Remedies Share Price

764.00 23.25 (3.14%)
31-Dec-2025 11:29 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1719.45
Dr. Reddys Lab 1266.30
Cipla 1499.20
Zydus Lifesciences 911.05
Lupin 2093.90
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×